Ticker brief
VRXA
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
6
authors 14d
4
crowd 14d
+0.3σ
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-10-07 → 2026-10-13 · now +0.20 (−1 bearish … +1 bullish)
Who spoke4
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Briefingcom | B | -2.26 | 3 | +0.22 |
| @CHItrader | B | -0.22 | 1 | +0.45 |
| @OpenOutcrier | C | · | 1 | +0.15 |
| @Analytica_X | B | -0.29 | 1 | +0.15 |
Recent signals6of 6 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-13 | @Briefingcom | +0.20 | Lists the largest premarket gaps, led by SCNI up 59.5% and SNDX down 10.4%. | · | tweet ↗ |
| 2026-10-12 | @Analytica_X | +0.15 | Summarizes four small-cap gainers and their daily percentage moves. | · | tweet ↗ |
| 2026-10-07 | @OpenOutcrier | +0.15 | Veraxa outlines an FDA-aligned strategy to reduce animal testing. | · | tweet ↗ |
| 2026-10-07 | @Briefingcom | +0.45 | Reports potent preclinical cancer-cell killing across ten patient-derived lung-cancer models. | · | tweet ↗ |
| 2026-10-07 | @Briefingcom | +0.00 | Lists premarket gap percentages; extraction is capped at the first six tickers. | · | tweet ↗ |
| 2026-10-07 | @CHItrader | +0.45 | Veraxa reports its lead T-cell engager killed tumor cells in ten patient-derived models. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.